Billiontoone (NASDAQ:BLLN) Stock: Insider Oguzhan Atay Sells 8,333 Shares

Billiontoone, Inc. (NASDAQ:BLLN) CEO Oguzhan Atay sold 8,333 shares of the stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $118.00, for a total transaction of $983,294.00. Following the completion of the sale, the chief executive officer directly owned 8,333 shares of the company’s stock, valued at approximately $983,294. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Wednesday, October 28th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $118.00, for a total transaction of $314,706.00.
• On Thursday, October 15th, Oguzhan Atay sold 5,150 shares of Billiontoone stock. The shares were sold at an average price of $100.23, for a total transaction of $516,184.50.
• On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $261,366.00.
• On Wednesday, October 14th, Oguzhan Atay sold 3,183 shares of Billiontoone stock. The shares were sold at an average price of $98.34, for a total transaction of $313,016.22.
• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The shares were sold at an average price of $97.61, for a total value of $260,325.87.
• On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The stock was sold at an average price of $93.79, for a total transaction of $1,563,197.93.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total value of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total value of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total value of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The shares were sold at an average price of $100.32, for a total transaction of $2,507,899.68.

Billiontoone Price Performance

BLLN stock traded down $1.52 during mid-day trading on Friday, hitting $113.32. The company had a trading volume of 468,077 shares, compared to its average volume of 547,126. The company has a quick ratio of 11.31, a current ratio of 11.69 and a debt-to-equity ratio of 0.17. The company has a market capitalization of $5.35 billion and a price-to-earnings ratio of 161.89. Billiontoone, Inc. has a 12-month low of $61.96 and a 12-month high of $150.44. The company has a 50-day moving average price of $103.45 and a 200 day moving average price of $96.57.

Billiontoone (NASDAQ:BLLN) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.15. The firm had revenue of $109.45 million for the quarter. Billiontoone had a net margin of 8.04% and a return on equity of 9.96%. On average, research analysts anticipate that Billiontoone, Inc. will post 0.80 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have commented on BLLN. BTIG Research decreased their target price on shares of Billiontoone from $142.00 to $130.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim increased their price objective on Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. JPMorgan Chase & Co. decreased their price objective on shares of Billiontoone from $145.00 to $130.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Finally, Zacks Research upgraded Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $126.25.

Hedge Funds Weigh In On Billiontoone

Several large investors have recently added to or reduced their stakes in the business. Sei Investments Co. bought a new position in Billiontoone during the first quarter valued at about $1,058,000. The Manufacturers Life Insurance Company lifted its position in shares of Billiontoone by 151.8% during the 1st quarter. The Manufacturers Life Insurance Company now owns 30,506 shares of the company’s stock valued at $2,408,000 after acquiring an additional 18,389 shares during the period. Wasatch Advisors LP boosted its stake in shares of Billiontoone by 40.2% in the 2nd quarter. Wasatch Advisors LP now owns 518,084 shares of the company’s stock valued at $62,160,000 after purchasing an additional 148,446 shares during the last quarter. Bank of America Corp DE boosted its holdings in Billiontoone by 8,603.4% in the 1st quarter. Bank of America Corp DE now owns 12,707 shares of the company’s stock worth $1,003,000 after buying an additional 12,561 shares during the period. Finally, Emerald Mutual Fund Advisers Trust grew its holdings in shares of Billiontoone by 11.9% in the first quarter. Emerald Mutual Fund Advisers Trust now owns 132,206 shares of the company’s stock worth $10,436,000 after purchasing an additional 14,072 shares during the last quarter.

Billiontoone Company Profile

BillionToOne, Inc is a molecular diagnostics company that develops tests designed to provide more sensitive and quantitative genetic information from blood samples. The company’s technology is based on its proprietary Quantitative Counting Template (QCT) platform, which is designed to measure DNA molecules with high sensitivity and support the detection of clinically meaningful genetic signals.

The company’s products include prenatal diagnostic and screening solutions marketed under the UNITY brand.